An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays by Höftberger, Romana et al.
An Optimized Immunohistochemistry Technique
Improves NMO-IgG Detection: Study Comparison with
Cell-Based Assays
Romana Höftberger1,2, Lidia Sabater1, Romain Marignier3, Fahmy Aboul-Enein4, Raphaël Bernard-Valnet3,
Helmut Rauschka4, Anne Ruiz3, Yolanda Blanco1, Francesc Graus1, Josep Dalmau5,6, Albert Saiz1*
1 Service of Neurology, Hospital Clínic, Universitat de Barcelona and Institut d´Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain,
2 Institute of Neurology, Medical University of Vienna, Vienna, Austria, 3 Team ONCOFLAM, Lyon Neuroscience Research Center INSERM U 1028/CNRS
5292, Lyon, France, 4 Department of Neurology, SMZ-Ost Donauspital, Vienna, Austria, 5 Institució Catalana de Recerca i Estudis Avançats (ICREA), IDIBAPS,
Hospital Clínic, Barcelona, Spain, 6 Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
Abstract
Cell-based assays (CBA) have increased the sensitivity of the neuromyelitis optica (NMO)-IgG/aquaporin-4-antibody
detection compared to classical tissue-based indirect assays. We describe the sensitivity of an optimized
immunohistochemistry (IHC-o) to detect NMO-IgG/aquaporin-4-antibody in comparison with that of two CBA: an in-
house (CBA-ih) and a commercial (CBA-c) assay (Euroimmun, Germany). Coded serum from 103 patients with
definite NMO and 122 inflammatory controls were studied by IHC-o, CBA-ih, and CBA-c. IHC-o used the same
protocol described to detect antibodies against cell surface antigens. CBA-ih used live cells transfected with the
aquaporin-4-M23-isoform. The sensitivity of the IHC-o was 74.8% (95% confidence interval [CI] 65-83) and was
similar to that of the CBA-ih 75.7% (95% CI 66-84) and the CBA-c 73.8% (95% CI 64-82). The specificity of the three
assays was 100% (95% CI 97-100). Interassay concordance was high, 100 of 103 samples were coincident in all
techniques. The optimized immunohistochemistry proves to be as sensitive and specific as the cell-based assays.
This assay extends the available tools for NMO-IgG/aquaporin-4-antibody detection.
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Neuromyelitis optica (NMO) is an inflammatory
demyelinating disease of the central nervous system (CNS)
characterized by predominant involvement of the optic nerves
and spinal cord. For long time, NMO was thought to be a
variant of multiple sclerosis (MS), although the prognosis and
the response to the therapy was different [1]. The identification
of a specific serum autoantibody marker by tissue-based
indirect immunofluorescence (IIF), NMO-IgG, that bound to
astrocytic membranes and the recognition of the target antigen
as the water channel aquaporin-4 (AQP4) [2], led to expand the
clinical spectrum of NMO to limited forms of the disease, to
define a new set of diagnostic criteria, and to expedite the
diagnosis and treatment of the patients [1,3,4,5,6,7,8].
Since the initial description of the NMO-IgG/AQP4-antibody,
several techniques of detection with different sensitivities and
specificities have been reported [9]. In a recent comparative
study, IIF was the least and cell-based assay transfected with
AQP4 (CBA) the most sensitive assay for NMO-IgG/AQP4-
antibody detection [10,11]. In spite of assay refinement, around
20-30% of patients clinically diagnosed with NMO still remain
NMO-IgG seronegative [10]. In neuronal autoimmune disorders
of the CNS (or autoimmune encephalitis) most of the
antibodies were initially identified using IIF or
immunohistochemical techniques [12]. These techniques allow
the possibility to identify new or coexisting antibodies. We
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e79083
observed that the optimized immunohistochemistry technique
(IHC-o) developed for the detection of antibodies against cell
surface/synaptic antigens [13], also identified the NMO-IgG
pattern, which was easily recognized compared with
conventional immunohistochemistry (IHC-c) [7,14].
The aim of the current study was to determine the sensitivity
and specificity of the IHC-o to detect NMO-IgG/AQP4-
antibodies, and compare them with those of conventional
tissue-based assays, including IIF and IHC-c, and two CBA, an
in-house assay (CBA-ih) with the AQP4-M23 isoform and a
commercial assay (CBA-c) [15].
Material and Methods
Patients
Serum samples from 103 patients with definite NMO
according to the revised diagnostic criteria of 2006 [5] (79%
female, mean age at sampling 42.1 years, range 7-82 years)
and 122 with inflammatory neurological diseases: 101 patients
with MS, 30 of them with paired serum and cerebrospinal fluid
(83 relapsing and 18 primary progressive MS) fulfilling the
McDonalds criteria [16], and 21 with neurological syndromes
associated with anti-neuronal antibodies (3 Hu, 2 Ri, 2 Yo, 3
CV2/CRMP5, 2 Ma2, 1 SOX, 3 GAD, 3 LGI1, and 2 CASPR2)
were tested by IHC-o, CBA-ih, and CBA-c. The NMO samples
were provided by 3 centers: Lyon Neuroscience Research
Center, France; Neuroimmunology Group, Hospital Clinic de
Barcelona, Spain; and the Department of Neurology, SMZ-Ost
Donauspital, Vienna, Austria [17]. Thirty-nine NMO samples
have been previously analysed by IIF [6] and other 43 samples
by IHC-c [14]. These samples were further re-analyzed by IIF
and IHC-c, respectively. Sera were coded before testing and all
studies were evaluated by two investigators (RH and AS),
blinded to the neurological diagnosis or results of the
conventional tissue-based assays.
Standard Protocol Approvals, Registrations, and
Patient Consents
Serum samples used in the study are deposited in the
collection of biological samples named "neuroinmunología"
registered in the biobank of  Institut d' Investigació Biomèdica
August Pi i Sunyer (IDIBAPS), Barcelona, Spain, the biobank
Neurobiotec (Hospices Civils de Lyon, France), and SMZost
Donauspital, Vienna, Austria (EK11-056VK). Considering that
the study was completely anonymous so no sample could be
identified to a particular patient, it was accepted to waive the
specific written informed consent from the patients or next of
kin by the Comitè Ético de Investigación Clínica of Hospital
Clínic de Barcelona. Animal handling procedures were
approved by the Local Ethics Committee (99/1 University of
Barcelona) and the Generalitat de Catalunya (1094/99), in
accordance with the Directive 86/609/EU of the European
Commission. The study as explained was approved by the
Ethical Committee of the Institutional Review Boards of the
University of Lyon, Hospital Clínic de Barcelona, and SMZost
Donauspital, Vienna.
Conventional immunohistochemistry technique (IHC-c)
and tissue-based indirect immunofluorescence (IIF)
We used adult male Spraguey Dawley rats that were
anaesthesized, sacrificed and perfused with 2%
paraformaldehyde. Rat brains were removed, sagittally
sectioned and fixed for 4 hours in 2% paraformaldehyde at
4°C. Subsequently, brains were cryoprotected with 20%
sucrose for 48h, embedded in freezing medium, and snap
frozen in isopentane chilled with liquid nitrogen. Seven micron
thick cryostat-cut sections from the cerebellum were defrosted
for 20 minutes, washed once in PBS and then incubated with
10% goat serum diluted in 0.03% Triton X-100 (Sigma-Aldrich,
St Louis, MO, USA) for 30 minutes. For IHC-c, sections were
incubated with patients´sera (1:500, diluted in 10% goat serum
in 0.03% Triton-X-100) for 3 hours at 37°C, then they were
washed 2x in PBS, labeled with biotinylated goat anti-human
IgG (Vector lab) (1:8000, diluted in PBS) for 30 minutes,
washed 2x in PBS, and incubated with avidin-biotin peroxidase
for 30 minutes at room temperature. The reactivity was
developed with diaminobenzidine for 1 to 1.5 minutes (Vector
lab).
For the IIF, we used the same protocol as described above,
but with sera diluted 1:50 and sections labeled with an Alexa
Fluor secondary antibody against human IgGs (1:500;
Molecular Probes, Invitrogen, Eugene, OR, USA) for 2h.
Optimized immunohistochemistry technique (IHC-o)
We used adult female Wistar rats that were sacrificed in a
CO2 chamber. Non-perfused rat brains were removed,
sagittally sectioned and fixed for 1h in 4% paraformaldehyde at
4°C. Subsequently, brains were cryoprotected with 40%
sucrose for 48h, embedded in freezing medium, and snap
frozen in isopentane chilled with liquid nitrogen. Seven micron
thick cryostat-cut sections were defrosted for 20 minutes,
washed once with PBS and then incubated with 0.3% hydrogen
peroxide for 15 minutes. After washing 3x with PBS, slides
were incubated with 5% goat serum in PBS for 1h, and then
labeled with patients´or control sera (1:200, diluted in 5% goat
serum) or CSF (1:2) at 4°C overnight. The next day, sections
were washed 3x in PBS, labeled with biotinylated goat anti-
human IgG (Vector lab) (1:2000, diluted in 5% goat serum) for
2h, washed 3x in PBS, and incubated with avidin-biotin
peroxidase for 1h at room temperature. The reactivity was
developed with diaminobenzidine for 7 minutes (Vector lab).
Cell-based assay
Two CBA were performed. A commercial (CBA-c) following
the manufacturer´s instructions (Euroimmun, Luebeck,
Germany) [15], and an in-house CBA (CBA-ih) with cells
transfected with the M23 isoform of AQP4 (the clone was a gift
from Dr. R. Marignier). Briefly, thirty-six hours after transfecting
HEK293 cells with the AQP4-M23 isoform, live cells were
incubated at room temperature with centrifuged serum 1:20
and CSF 1:2 (diluted in DMEM with HEPES and 1% bovine
serum albumine) for 30 minutes. After removing the media and
washing with DMEM with HEPES and 1% BSA, HEK cells were
fixed with 1% paraformaldehyde for 15 minutes and
permeabelized with 0.3% Triton X-100 (Sigma-Aldrich, St
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Louis, MO, USA). HEK cells were then immunolabeled with a
rabbit polyclonal anti-AQP4 antibody (1:500; Sigma-Aldrich) for
1h at room temperature, followed by the corresponding Alexa
Fluor secondary antibodies against human and rabbit IgGs
(1:1000; Molecular Probes, Invitrogen, Eugene, OR, USA).
Statistical analysis
The receiver operating characteristic curve (ROC) analysis
was used for the assessment of the diagnostic accuracy of
these tests. The degree of concordance between two assays
was assessed by the kappa statistic, which measures
agreement beyond chance. Kappa (κ) equals 1.0 for perfect
agreement and values above 0.8 are considered to represent
very good agreements. We used SPSS software version 18.0
for all calculations.
Results
Staining pattern of NMO-IgG/AQP4-antibodies with the
optimized immunohistochemistry technique
The IHC-o specifically detects antibodies targeting AQP4 on
the astroglial cell surface. The staining pattern on rat brain
sections is characterized by 1) reticular labeling of glial
processes in the granular layer of the cerebellum (Figure 1A),
forming basket-shaped branches around cell bodies of Purkinje
cells (Figure 1B arrow) 2) labeling of the glia limitans
perivascularis throughout the whole brain (Figure 1B
arrowheads), and 3) fine process staining in the neuropil of the
hippocampus with denser immunoreactivity in the stratum
lacunosum moleculare, the molecular layer of the dentate
gyrus and a thin layer of AQP4-positivity in the subgranular
zone (Figure 1C, D arrowheads). Patients with low antibody
titer may only show staining of the granular layer of the
cerebellum and labeling of the glia limitans perivascularis.
Sensitivity and specificity of the NMO-IgG/AQP4-
antibody assays
The sensitivity of the IHC-o was 75% (77 of 103), the CBA-ih
76% (78 of 103), and the CBA-c 74% (76 of 103) (Table 1).
Interassay concordance overall was high, 100 of 103 were
coincident in all techniques (Table 2). The specificity of the
three assays was 100%. The concordance kappa value
between CBA-ih and IHC-o was 0.99 (95% confidence interval
[CI] 0.987-0.992), between CBA-ih and CBA-c 0.980
(0.975-0.985) and between IHC-o and CBA-c 0.970
(0.962-0.977) (p <0.0001 for all values). The interobserver
Figure 1.  Staining pattern of a patients´ serum with NMO-IgG/AQP4-antibodies in rat brain.  Patients´serum shows extensive
labeling of the granular layer of the cerebellum (A). Note the reticular staining pattern, forming basket-shaped processes around cell
bodies of Purkinje cells (arrow), and the glia limitans perivascularis (arrow heads) (B). Immunoreactivity of hippocampus shows
laminar specificity with strongest staining in the stratum lacunosum moleculare (SLM), molecular layer of the dentate gyrus (ML) and
a thin layer of AQP4-positivity in the subgranular zone (arrow heads) (C, D; rectangle in C enlarged in D). SO, stratum oriens; SP,
stratum pyramidale; SR, stratum radiatum; DGC, dentate granule cell layer; H, hilus. Magnification: A, D x100; B, x400; C, x40; .
doi: 10.1371/journal.pone.0079083.g001
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variability for the IHC-o was low and only discordant in two
samples, the concordance kappa value between the two
investigators was 0.980 (95% CI 0.974-0.985). The IIF and
IHC-c analysis showed a complete agreement with the
previous results. The IHC-o detected 6 more positive cases
than the IIF (24 of 39; 61.5% vs 46%) and 5 more than the
IHC-c (33 of 43; 77% vs 65%) (Table 2).
Discussion
The identification of NMO-IgG/AQP4-antibody is essential to
establish an early diagnosis of NMO and to promptly initiate the
appropriate immunotherapy. Several methods for the detection
of NMO-IgG/AQP4-antibody are available, which differ in their
sensitivities and specificities [9]. In a recent multicenter
comparative study, assays based on binding of IgG to cells
transfected with AQP4 proved to be the most and IIF the least
sensitive method of detection [10]. However, screening for
NMO-IgG/AQP4-antibody by tissue-based assays is still
recommended as it is cheap and can demonstrate different or
new antibodies associated with NMO disease spectrum, while
the CBA only demonstrates the antigen of interest
overexpressed in the cells.
In this blinded study we show that the IHC-o commonly used
to identify recognizable staining patterns of antibodies against
cell surface/synaptic proteins also detects NMO-IgG/AQP4-
antibodies with a higher sensitivity compared to the
conventional tissue-based assays, without losing specificity. In
fact, with this method our previously reported sensitivity of 65%

























































CBA-ih=in-house cell-based assay. IHC-o=optimized immunohistochemical
technique. CBA-c=commercial cell-based assay. NMO=neuromyelitis optica. ROC-
AUC=receiver operating characteristic curve-area under the curve. CI=confidence
intervals. Pos. LR=positive likelihood ratio. Negative LR=negative likelihood ratio.
n.a.=not applicable.
doi: 10.1371/journal.pone.0079083.t001
increased to 77% [14]. This high sensitivity and specificity of
IHC-o compares well with that of CBA; the agreement with
results obtained with the CBA-ih was very high and only one
sample was not identified with the IHC-o. It is important to bear
in mind that the aim of the current study was to compare the
sensitivity and specificity of different methods of NMO-IgG/
AQP4-antibody detection but not to address their value in the
diagnosis of NMO/NMO spectrum disorders, which is limited by
bias in the selection of the samples.
The IHC-o identifies a characteristic staining pattern that
corresponds well to the anatomical distribution of AQP4 in the
brain [18]. The pattern is well recognized despite the presence
of other antibodies (e.g. NMDAR antibodies); for example, we
did not find false positive results despite the large
representation of samples with known neuronal antibodies
included as controls. As expected, the sensitivity of the
commercial CBA-c was also very high.
We realize that the sensitivity of the IHC-o may depend on
laboratory expertise. In some patients with very low titer of
antibodies, the IHC-o may show only weak staining of the
granular cell layer of the cerebellum with lower immunostaining
of the glia limitans perivascularis. In such cases and especially
in clinically well-selected patients, we suggest complementing
this study with the commercial CBA-c. In fact, none of the
patients of the current study was misdiagnosed when
combining both techniques.
The number of assays for NMO-IgG/AQP4-antibody
detection is increasing, but seronegative NMO-IgG/AQP4-
antibody status remains a challenge. Myelin-oligodendrocyte
glycoprotein antibodies have been reported in a few NMO-IgG/
AQP4-antibody seronegative patients with NMO [19,20,21]; it is
reasonable to expect that novel antibodies will be identified in
other NMO seronegative patients. Detection of some of these
antibodies will be facilitated by the immunohistochemistry
reported here. For example, in the past 12 months we tested
over 300 samples from patients in whom NMO was suspected.
In one patient with isolated longitudinally extensive transverse
myelitis, the IHC-o identified LGI1 antibodies instead of NMO-
IgG; the identity of LGI1 was subsequently confirmed with the
appropriate CBA. In another patient, a neuropil pattern of brain
immunostaining was detected, and an antibody against a
neuronal cell-surface antigen was subsequently confirmed with
immunostaining of live hippocampal neurons. Altogether, these
data support the additional value of using tissue-based assays.
In conclusion, this study shows that the indicated IHC-o is
sensitive to detect NMO-IgG/AQP4-antibody and the findings
compare well with CBA. This type of IHC expands the available
tools for NMO-IgG/AQP4-antibody detection, and offers a
technique that has the advantage to detect other cell surface
antibodies that would be missed if the NMO-IgG/AQP4-
antibody detection is directly done by CBA.
Optimized Tissue-Based Assay for NMO-IgG Detection
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e79083
Table 2. Concordance of the different assays.
NMO cases France (n=39)IHC-o CBA-ih CBA-c IIF NMO cases Spain(n=43)IHC- o CBA- ihCBA-c IHC-c NMO cases Austria (n=21)IHC- o CBA- ihCBA- c
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + +  + + + +  + + +
 + + + -  + + + +  + + +
 + + + -  + + + +  + + +
 + + + -  + + + +  - + +
 + + + -  + + + +     
 + + - -  + + + +     
 + + - -  + + + +     
 - - - -  + + + +     
 - - - -  + + + +     
 - - - -  + + + +     
 - - - -  + + + +     
 - - - -  + + + -     
 - - - -  + + + -     
 - - - -  + + + -     
 - - - -  + + + -     
 - - - -  + + + -     
 - - - -  - - - -     
 - - - -  - - - -     
 - - - -  - - - -     
 - - - -  - - - -     
 - - - -  - - - -     
 - - - -  - - - -     
      - - - -     
      - - - -     
      - - - -     
      - - - -     
Pat. 24/ 39 24/ 39 22/ 39 18/ 39 Pat. 33/ 43 33/ 43 33/ 43 28/ 43 Pat. 20/ 21 21/ 21 21/ 21
Co. 0/ 122 0/ 122 0/ 122           
NMO=neuromyelitis optica. IHC-o=optimized immunohistochemical technique. CBA-ih=in-house cell-based assay. CBA-c=commercial cell-based assay. IIF=indirect
immunofluorescence. Pat=patients. Co=controls.
doi: 10.1371/journal.pone.0079083.t002
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